In recent years we have seen significant regulatory changes in Canada that may affect market access of new drugs and biologics. As we look ahead to 2021, the legal experts at Smart & Biggar report on the recent developments to help innovative life sciences companies navigate the Canadian patent and regulatory landscape.
Smart & Biggar partners Daphne Lainson, Nancy Pei and David Schwartz recorded this timely update on patented medicines in Canada on Thursday, September 10th, including:
Patented medicines pricing reform
- Status of legal challenges to the amended Patented Medicines Regulations
- Coming into force of the new pricing regime of the Patented Medicine Prices Review Board (PMPRB)
- Implications of new law for grandfathered products, line extensions, “gap” drugs and new patented drugs
Patent term extension
- Recent jurisprudence concerning Certificates of Supplementary Protection
- Update on Patent Term Adjustment
Patent law changes
- Patent and patent application maintenance: new risks, greater certainty
- New options for maintaining pendency
- COVID-19 “compulsory licensing”
Events & Webinars
-
- BIO 2025: Connect with Smart & Biggar’s leading Canadian Life Sciences team
Smart & Biggar's leading Life Sciences team will travel to Boston to attend this year's Bio International Convention from June 16-19, 2025. Read More -
- INTA 2025: Connecting with Smart & Biggar's leading IP team
Smart & Biggar team members will attend the 2025 International Trademark Association Annual Meeting from May 17-21, 2025. Read More -
From Idea to Intellectual Property – IP as a Cultural shield? Protecting Traditional Knowledge and Expression
In this IPH Limited podcast, Meika Ellis explores the IP of Indigenous knowledge and cultural expression and the tools that can help protect it while ensuring that Indigenous communities retain contro... Read More